Think about being the parent of a child born with spinal muscular atrophy — a devastating genetic condition that progressively destroys the motor neurons controlling movement, swallowing, and breathing, typically killing affected infants before their second birthday if left untreated.
Now imagine that a single injection exists that can essentially halt that destruction — not manage it, not slow it modestly, but genuinely halt it — by delivering a corrected copy of the defective gene directly into the child’s cells. Imagine that this treatment has demonstrated outcomes so remarkable that children who would otherwise have lost all muscle function are sitting up, standing, and in some cases walking. Imagine that this injection works best — perhaps only meaningfully — in the first few months of life, before irreversible neurological damage accumulates.
Now imagine learning that this injection costs $2.1 million. That it costs more than any other drug in human history at the time of its approval. That your insurance company will spend months deliberating whether to cover it while your child’s window of maximum therapeutic benefit closes week by week. That families in countries without adequate insurance systems or healthcare funding will simply never receive it. That the child down the street from you — born with the identical genetic condition, facing the identical trajectory of disease — will not receive this treatment because their family’s circumstances sit on the wrong side of an economic line that has nothing to do with medicine and everything to do with markets.
This is not a hypothetical. This is the story of Zolgensma, the gene therapy for spinal muscular atrophy approved by the FDA in 2019 and manufactured by Novartis. And it is the story that encapsulates the central moral crisis of gene therapy commercialization — a crisis that combines genuine scientific triumph with a pricing model so extreme that it raises fundamental questions about what medicine is for, who gets to benefit from scientific progress, and whether the commercialization of biotechnology has produced a system that systematically denies its most powerful treatments to the patients who need them most.
Gene Therapy and Why It Is Different
To appreciate why gene therapy pricing is a distinct and particularly acute ethical problem rather than simply the standard pharmaceutical pricing debate in a more extreme form, you need to understand what gene therapy actually is and how it differs fundamentally from conventional pharmaceutical treatments. Most drugs treat disease by managing its symptoms or modifying the biological processes through which it causes harm — they are ongoing interventions that require continuous administration and provide benefit for as long as they are taken. Stop taking them, and the disease typically returns or progresses.
Gene therapy is categorically different. Rather than managing the downstream consequences of a genetic defect, gene therapy addresses the defect itself — delivering functional genetic material into a patient’s cells to correct, replace, or supplement the defective gene that is causing the disease. The goal is not management but correction — not a treatment that patients take for life but a one-time intervention that permanently alters the cellular machinery producing the disease. In the most successful applications, gene therapy is essentially a cure — a single administration that provides lasting, potentially lifetime benefit.
This fundamental difference between gene therapy and conventional pharmaceutical treatment is what makes its pricing both more justifiable in theory and more problematic in practice than standard drug pricing debates might suggest.
The argument that a one-time treatment providing lifetime benefit is worth more than years of chronic disease management has genuine logical force — when you calculate the cumulative cost of decades of conventional treatment, hospitalizations, disability management, and lost productivity, the economics of a one-time cure can look quite different from the sticker price alone. But the practice of translating that theoretical lifetime value into an upfront price that no individual patient, most insurance systems, and most national health services can practically afford produces an access barrier that the theoretical value argument does nothing to address for the patients who cannot get past it.
The Price Explosion: How Gene Therapies Got So Expensive
The trajectory of gene therapy pricing has followed a pattern that, once you understand the underlying dynamics, has a disturbing internal logic. The first approved gene therapies set price precedents that subsequent manufacturers have used as anchors, and each new approval has pushed the ceiling higher in ways that have normalized pricing that would have been considered absurdly excessive even a decade ago. Understanding how this happened requires looking honestly at the forces that drive pricing decisions in the pharmaceutical industry and how they interact with the specific characteristics of gene therapy development.
Drug development costs are genuinely enormous — the pharmaceutical industry’s estimate of $2.6 billion as the average cost of bringing a new drug to market, though contested by critics who argue it dramatically overstates true development costs by including cost of capital and failed drug candidates, is at least directionally correct in indicating that bringing a new therapeutic to market requires massive upfront investment with highly uncertain probability of success.
Gene therapy development carries additional costs and challenges beyond those of conventional drug development — the manufacturing of viral vectors used to deliver genetic material to cells is extraordinarily complex, the regulatory requirements for demonstrating safety in irreversible genetic interventions are appropriately rigorous, and the clinical trial populations for rare genetic diseases are tiny, making per-patient trial costs extremely high.
The economics of rare disease drug development create a structural pricing pressure that is distinct from blockbuster drug economics. When a company develops a drug for a condition affecting millions of people, the development costs can be spread across a large patient population, allowing profitable pricing at relatively modest per-patient levels.
When a company develops a gene therapy for a condition affecting a few thousand patients globally, the same development costs must be recovered from a tiny patient population, creating arithmetic pressure toward high per-patient pricing even if profit margins are modest. This is the orphan drug economics problem that existing regulatory incentives — orphan drug designation providing market exclusivity and tax benefits — were designed to address by encouraging rare disease development, but which interact with unconstrained pricing to produce extreme prices that the orphan drug frameworks’ designers may not have fully anticipated.
The Profiteering Question Nobody Wants to Answer Directly
The genuinely difficult question that the rare disease economics argument leaves unresolved is where legitimate cost recovery and reasonable profit end and where profiteering begins — and whether the pricing of approved gene therapies reflects the former or the latter. This is not a question that the pharmaceutical industry is eager to answer with specificity, and the opacity of pharmaceutical cost accounting makes independent assessment extremely difficult.
What we do know is instructive. The Institute for Clinical and Economic Review, an independent organization that evaluates the cost-effectiveness of medical treatments, has analyzed the pricing of multiple approved gene therapies and found that most are priced significantly above the threshold at which they would be considered cost-effective even using generous lifetime value frameworks. Zolgensma, priced at $2.1 million, was assessed by ICER as potentially cost-effective at between $310,000 and $900,000 depending on assumptions about treatment durability — meaning the actual price was between two and seven times what an independent assessment of value would justify.
Novartis has acknowledged that Zolgensma’s pricing was set using a value-based framework that calculated the treatment’s worth against the lifetime cost of disease management and caregiver burden — a methodology that has some theoretical defensibility but that is applied in a market context where the company has monopoly pricing power, no meaningful competitive constraint, and customers (insurance systems and individual patients) who are, literally, captive to the availability of a life-saving treatment. Pricing a product at the maximum the market will bear when the market in question consists of dying children and desperate parents is a strategy whose ethical acceptability is not resolved by calling it value-based.
The Global Access Catastrophe
The pricing of gene therapies produces its most devastating consequences not in the United States, where insurance systems and manufacturer assistance programs provide at least some mechanism for access even if imperfect and bureaucratically tortured, but in the global context where most of the world’s population lives without the insurance infrastructure that makes even imperfect access possible. The global dimension of gene therapy access is a humanitarian crisis of considerable proportions that receives far less attention than the domestic American insurance coverage debate because its victims are invisible to the media systems and political processes that shape health policy discourse.
Spinal muscular atrophy — to stay with the Zolgensma example — affects people everywhere in the world at roughly similar rates. The mutation causing the disease does not check passports or consult economic indices before occurring. A child born with SMA in Nigeria, Bangladesh, Bolivia, or the Philippines faces the same medical trajectory as a child born with SMA in New York or London, and would benefit equally from the same treatment. But the practical probability of that child in Dhaka or Lagos receiving Zolgensma at its current price is essentially zero. The treatment that exists and works is simply not accessible to the vast majority of people who need it.
This situation is sometimes described using the language of market economics — the drug is available to those who can pay for it, which is how markets work — as if describing the distribution mechanism accurately is sufficient to address the ethical problem it produces. But a market framework for drug distribution in which the ability to benefit from a treatment is identical across the global population while the ability to access it varies by several orders of magnitude based on birthplace is not simply a market outcome. It is a moral failure of the systems we have built for translating scientific knowledge into human health, and calling it a market outcome doesn’t make it any less of a moral failure.
Insurance Systems Under Unprecedented Strain
In countries with developed insurance systems — whether private insurance markets like the United States or national health systems like the UK’s NHS — gene therapy pricing is creating coverage challenges that are straining established frameworks in ways they were not designed to handle. Insurance systems, whether private or public, function through risk pooling — spreading the costs of individual medical events across large populations so that no individual faces catastrophic financial exposure from a health event they could not have predicted or prevented.
Gene therapy pricing challenges this risk-pooling model in several ways simultaneously. The one-time nature of gene therapy means that the full cost falls in a single year of coverage, rather than being spread across the years of a patient’s insurance enrollment. An insurer who covers a patient receiving a $3 million gene therapy in a given year may recover very little of that cost through future premium payments if the patient then moves to a different insurer — creating an incentive for each insurer to minimize coverage of gene therapies and maximize the probability that their competitors bear the cost.
The NHS in the United Kingdom — which operates as a national single payer that doesn’t face the adverse selection problems of competing private insurers — has still found gene therapy pricing intensely challenging. NICE, the UK body responsible for evaluating new treatments for NHS coverage, has repeatedly found gene therapies difficult to recommend at their list prices under standard cost-effectiveness frameworks, resulting in protracted negotiations between NHS England and manufacturers that often result in access delays measured in years. During those years, patients with time-sensitive conditions — particularly degenerative genetic diseases where treatment is most effective when administered early — are irreversibly harmed by the delay that pricing negotiations create.
The Orphan Drug Paradox
The regulatory framework designed to encourage pharmaceutical development for rare diseases — the Orphan Drug Act in the United States and equivalent legislation in other jurisdictions — has created a paradox that directly contributes to the gene therapy pricing crisis. By granting enhanced market exclusivity, tax credits for research expenses, and expedited regulatory pathways to drugs targeting conditions affecting small patient populations, orphan drug legislation was intended to make rare disease drug development economically viable for pharmaceutical companies that would otherwise have no incentive to pursue it.
The framework has succeeded in its primary objective — the number of rare disease treatments developed and approved has increased dramatically since the Orphan Drug Act was passed in 1983. But it has done so by creating economic incentives that encourage extremely high pricing without any countervailing mechanism to ensure that the resulting drugs are actually accessible to the patients they were developed for. The orphan drug designation that makes development economically viable also creates the monopoly pricing power that makes the resulting products unaffordable. The legislative drafters apparently assumed that market forces or goodwill would constrain pricing to accessible levels — an assumption that has proven dramatically incorrect.
The gene therapy context is particularly stark because gene therapies almost always target rare diseases — the very conditions for which orphan drug incentives apply — and because their one-time treatment paradigm and manufacturing complexity create extreme per-patient costs that push pricing dynamics toward the astronomical. The framework that was supposed to ensure patients with rare diseases could access innovative treatments has instead produced a system in which genuinely transformative treatments are developed and approved but remain inaccessible to most patients who could benefit from them.
Manufacturer Assistance Programs: The Fig Leaf That Doesn’t Cover Much
Pharmaceutical companies developing gene therapies are keenly aware of the access criticism their pricing generates, and they typically respond by establishing patient assistance programs — manufacturer-funded mechanisms through which uninsured or underinsured patients can receive treatments at reduced or no cost. These programs are real, and they provide genuine benefit to some individual patients who would otherwise have no access. But they are also structurally inadequate as a solution to the access problem gene therapy pricing creates, and understanding why matters for evaluating whether they represent a genuine commitment to access or primarily a public relations mechanism.
Manufacturer assistance programs are discretionary — companies establish them voluntarily, define their eligibility criteria without external oversight, control who qualifies and who doesn’t, and can modify or discontinue them at any time. They are opaque — reporting requirements for assistance program utilization are minimal, making it impossible to independently verify how many patients actually receive treatment through these programs versus how many are turned away.
They are designed primarily for the American market and the small number of other high-income countries with comparable healthcare systems, providing essentially no benefit for the majority of the world’s population in low- and middle-income countries. And they create no sustainable access pathway — a company that provides a therapy to qualifying patients at reduced cost today can change that policy tomorrow without any external check.
The existence of manufacturer assistance programs also creates a perverse dynamic in coverage negotiations, where insurers can point to the programs as evidence that patients have alternative access pathways and therefore decline coverage — while the programs simultaneously maintain price levels that make coverage economically untenable. The assistance program becomes both the manufacturer’s justification for maintaining high list prices and the insurer’s justification for not covering the therapy — and patients fall into the gap between these two institutional self-interests.
The Installment Payment Innovation: Interesting but Insufficient
One of the more creative financial innovations that the gene therapy pricing crisis has generated is the concept of installment-based payment models — replacing the single upfront payment of the full treatment cost with a series of payments spread over time and potentially conditioned on demonstrated treatment outcomes. If a gene therapy costs $3 million upfront, insurers face the full cost in a single year with no protection against the risk that the treatment turns out to be less durable or effective than clinical trial data suggested. An installment model that spreads payments over ten years and reduces or eliminates payments if the treatment’s effects diminish could theoretically address several of the access and financing challenges simultaneously.
Novartis implemented exactly this kind of payment arrangement for Zolgensma — offering an installment plan and outcomes-based payment adjustments — and several other gene therapy manufacturers have explored similar approaches. The concept is genuinely interesting and represents a more sophisticated engagement with the financing challenges of one-time, high-cost treatments than simply insisting that payers absorb the full upfront price. But the innovation is insufficient as a comprehensive solution for several reasons that are worth examining honestly.
Installment payment models help with cash flow management for payers but don’t reduce the total cost of treatment — spreading $3 million over ten years doesn’t change the fact that the treatment costs $3 million. For the global majority of patients in healthcare systems that can’t afford $3 million over any timeframe, the payment structure is irrelevant. And the administrative complexity of implementing outcomes-based payment arrangements — defining measurable outcomes, establishing assessment protocols, adjudicating disputes about whether outcomes have been achieved — creates implementation challenges that limit the practical availability of these innovative payment models.
The Research Funding Problem: Where Did the Money Come From?
Any comprehensive analysis of gene therapy pricing must engage with the question of public research funding and its relationship to the commercial pricing of therapies that public research helped create. This relationship is more significant in gene therapy than in almost any other therapeutic area because the foundational science and much of the early clinical development of gene therapy was conducted in academic settings supported primarily by public research funding through institutions like the National Institutes of Health.
The academic research funded by NIH grants developed the viral vector delivery systems that most gene therapies use. The basic understanding of how to design therapeutic genetic constructs was built in publicly funded university laboratories. The early clinical trials that demonstrated proof of concept for gene therapy approaches were conducted with substantial public research support. The cumulative public investment in the scientific knowledge base that commercial gene therapy builds upon is enormous — yet the commercial translation of that publicly funded knowledge into approved therapies occurs through a system that provides essentially no mechanism for public funding to translate into public access.
The pharmaceutical companies that purchase or license the intellectual property developed in publicly funded research, invest the additional capital required to conduct pivotal clinical trials and navigate the regulatory process, and manufacture and market the resulting therapies do provide genuinely valuable services that deserve compensation. But the current system allows them to appropriate essentially unlimited value from a scientific knowledge base that was collectively created and collectively funded, without any corresponding obligation to ensure that the resulting therapies are collectively accessible.
What Differential Pricing Could Actually Accomplish
One of the most practically achievable reforms to the gene therapy access problem is systematic differential pricing — the practice of charging different prices in different markets based on each market’s ability to pay, rather than charging a single global price set at the level the wealthiest market will bear. Differential pricing is not a novel concept in pharmaceutical markets — it exists in various forms for many conventional drugs, with manufacturers charging lower prices in lower-income countries than in high-income ones — but it has been applied inconsistently and often inadequately to gene therapies.
The theoretical case for differential pricing is straightforward. If a gene therapy is priced at a level that is accessible to insurance systems in the United States and other high-income countries, but completely inaccessible to middle-income countries whose healthcare systems could potentially afford it at a substantially lower price, then charging that lower price in those markets generates revenue that contributes to cost recovery without displacing any sales that would otherwise occur at the higher price. This is basic price discrimination economics — charging different prices in markets with different demand elasticities maximizes both total revenue and total access simultaneously.
The practice of differential pricing is complicated by several real-world factors including parallel trade — the risk that low-priced products sold in low-income markets will be reimported into high-income markets, undermining the high-price tier — and political sensitivity about making explicit what implicit differential pricing makes deniable. But these complications are manageable with appropriate regulatory frameworks, and the access benefits of systematic differential pricing would be significant. Countries like Brazil, Mexico, China, India, and the larger Southeast Asian economies could potentially afford gene therapies at prices far below the current list prices in the United States, if manufacturers were willing to engage with differential pricing seriously rather than tokenistically.
The Role of Government: Regulation, Negotiation, and Public Options
The most powerful lever for addressing the gene therapy pricing crisis is government action, and the question of what form that action should take is one of the most important health policy debates of the coming decade. Governments have multiple tools available for addressing pharmaceutical pricing — negotiation power through public payer systems, regulatory frameworks that condition approval or market exclusivity on pricing commitments, compulsory licensing provisions that allow governments to override patents in public health emergencies, and direct government involvement in the development or manufacture of treatments where market mechanisms have failed.
The Inflation Reduction Act in the United States created new Medicare negotiating authority that, for the first time, allows the federal government to directly negotiate prices for certain drugs — a significant policy shift that could eventually be extended to gene therapies. The European Union’s pharmaceutical legislation reforms underway include provisions for enhanced affordability conditions attached to market approval. Several governments have issued or seriously threatened compulsory licenses for specific expensive drugs, creating negotiating leverage even when the licenses are not ultimately issued. These government actions represent genuine movement toward addressing the pricing crisis, but they have been cautious and incremental relative to the scale of the problem.
A more ambitious government response would involve conditioning publicly funded research on affordability obligations — requiring that therapies substantially developed with public research funding be available at prices accessible to public payers. This approach, sometimes called the “reasonable pricing” condition, was actually applied by NIH to certain publicly funded drug research in the 1990s before being discontinued under pharmaceutical industry pressure. Its revival in an era of $3 million gene therapies would represent a logical application of the principle that public investment should serve public health objectives.
The Race Between Science and Ethics
One of the most striking features of the gene therapy pricing crisis is the gap between the pace of scientific development and the pace of ethical and policy development. The science of gene therapy has advanced at extraordinary speed — from the first approved gene therapies in the early 2010s to dozens of approved products targeting conditions across virtually every organ system, with a pipeline of hundreds more in clinical development. The ethical frameworks, policy tools, and institutional arrangements needed to ensure that this scientific progress translates into equitable health outcomes have developed at a fraction of that speed.
This gap between scientific capability and ethical infrastructure is not unique to gene therapy — it characterizes many domains of emerging biotechnology — but it has particularly acute consequences in gene therapy because the treatments being developed address conditions for which alternatives are often inadequate or nonexistent. When a one-time treatment can cure a child of a devastating genetic disease, the moral urgency of that capability is not diminished by the pricing system that makes it inaccessible. The urgency of the child’s need is unchanged by the pricing model. What changes is whether we, as a society, have built the ethical and institutional frameworks needed to ensure that the scientific achievement actually reaches the patient.
The Next Generation: CRISPR and the Pricing Horizon
Looking ahead, the gene therapy pricing crisis is set to intensify rather than resolve naturally as next-generation gene editing technologies — particularly CRISPR-Cas9 based therapies — move through clinical development and toward commercial approval. CRISPR therapies have the potential to address a substantially wider range of genetic conditions than current viral vector-based gene therapies, including common conditions like sickle cell disease that affect millions of patients rather than thousands, and the first CRISPR therapy approvals — Casgevy for sickle cell disease and beta-thalassemia — have already arrived with price tags in the $2-3 million range.
The arrival of gene therapies for relatively common conditions like sickle cell disease — a condition that disproportionately affects people of African descent globally — at prices calibrated to high-income market willingness to pay creates a particularly stark embodiment of the equity problem. Sickle cell disease causes enormous suffering in sub-Saharan Africa, where it is highly prevalent but where the populations affected have the least access to expensive treatments. A cure for sickle cell disease that can only be delivered in high-income countries to patients with comprehensive insurance coverage is not, in any meaningful sense, a cure for sickle cell disease globally.
Conclusion
The commercialization of gene therapy pricing does make these treatments inaccessible to the patients who need them most — not in some marginal or theoretical sense but actually, consequentially, and in ways that produce real suffering and death among people with real names and real families who are being denied treatments that exist and work and could change or save their lives. This is not a comfortable conclusion to reach about an industry that is simultaneously producing some of the most remarkable scientific achievements in human history. The science of gene therapy deserves celebration and support. The pricing system through which its products are commercialized deserves serious challenge and reform.
The gene therapy pricing crisis is not an inevitable consequence of the biology or the economics of rare disease drug development. It is the product of a specific set of policy choices — about intellectual property, about market exclusivity, about the relationship between public research funding and commercial pricing, about the absence of countervailing negotiating power for payers, and about the ethical frameworks within which pharmaceutical companies set prices. Those are choices that societies have the capacity to make differently, and the urgency of making them differently grows with every gene therapy approval that demonstrates both what science is now capable of achieving and how systematically the current system prevents that achievement from reaching the patients it was meant to serve.
Frequently Asked Questions
Why are gene therapies so much more expensive than conventional pharmaceutical treatments, and is there any legitimate justification for prices in the millions of dollars?
Gene therapy prices reflect a combination of genuine cost factors and market power dynamics that are important to distinguish. Legitimate cost factors include the extraordinary complexity of manufacturing viral vectors — the biological delivery systems most gene therapies use — which requires sophisticated specialized facilities and has high failure rates in production. Development costs for rare disease treatments are high per patient because small trial populations make each trial subject extremely expensive, and regulatory requirements for demonstrating safety in irreversible interventions are appropriately rigorous. However, these genuine cost factors do not straightforwardly justify prices in the millions of dollars. Independent analyses by health technology assessment organizations consistently find that approved gene therapies are priced significantly above what cost-effectiveness calculations would justify even using generous assumptions about lifetime value. The gap between what can be genuinely justified by cost recovery and reasonable profit and what manufacturers actually charge reflects monopoly pricing power in markets where competition is absent and patients are, essentially, captive to the availability of life-saving treatment.
How do insurance companies in the United States typically make coverage decisions for gene therapies, and how long does the process take?
Insurance coverage decisions for gene therapies in the United States involve a complex, multi-stage process that typically begins when a manufacturer submits clinical and economic evidence to major insurers and pharmacy benefit managers for review. Insurers assess clinical evidence for safety and efficacy, conduct or commission their own cost-effectiveness analyses, negotiate pricing and potential outcomes-based arrangements with manufacturers, and develop coverage criteria that define which patients qualify based on diagnosis, disease severity, prior treatment history, and other factors. This process routinely takes six to eighteen months after FDA approval, during which insurance coverage is either unavailable or inconsistent across different insurers. For conditions like spinal muscular atrophy where treatment is most effective when administered in the first months of life, coverage delays of this duration can directly determine whether a patient receives meaningful therapeutic benefit. Patients who identify the treatment through newborn screening but face insurer delays often suffer irreversible neurological progression during the coverage determination period.
Are there countries where gene therapy access is being handled more equitably than in the United States, and what can be learned from their approaches?
Several countries have developed approaches to gene therapy coverage and pricing that produce better access outcomes than the American system, though none has fully solved the access problem. Germany’s system of mandatory health technology assessment followed by mandatory pricing negotiations with manufacturers, conducted through its statutory health insurance system, has produced some successful negotiations that resulted in access at prices lower than German list prices and comparable international ones. Norway’s managed access program allows conditional coverage of treatments pending development of longer-term outcome data, enabling earlier access while managing financial risk for the national system. Several middle-income countries have engaged in direct negotiation for gene therapies used in public programs, including Brazil’s successful negotiation for Zolgensma at a price substantially below the U.S. list price. The common thread in more successful approaches is countervailing bargaining power — whether through government negotiating authority, international price referencing systems, or coordinated payer negotiations — that limits manufacturers’ ability to charge prices calibrated purely to what the most desperate payers will accept.
What would a more ethical and sustainable system for gene therapy pricing and access actually look like?
A more ethical and sustainable system for gene therapy development and access would integrate several interlocking reforms. Public research funding would include affordability conditions — requiring that therapies substantially developed with public funds be available at prices accessible to public payers. Regulatory market exclusivity periods would be conditioned on demonstrated reasonable access commitments rather than granted unconditionally. Government payers would have statutory negotiating authority with meaningful countervailing power, rather than being price takers in markets where manufacturers hold all the leverage. Systematic global differential pricing frameworks, supported by enforceable restrictions on parallel trade, would ensure that lower-income markets can access treatments at prices reflecting their ability to pay. Outcomes-based payment arrangements would be standardized and simplified to make them practically implementable. And international coordination mechanisms — potentially through WHO frameworks — would support collective negotiating approaches that give global health systems more leverage than they currently have in individual negotiations with manufacturers.
What is the likely trajectory of gene therapy pricing over the next decade, and will competition eventually bring prices down?
The trajectory of gene therapy pricing over the next decade is likely to involve continued upward pressure from new approvals, partially offset by competitive price reductions in specific therapeutic areas where multiple products target the same condition. In therapeutic areas where multiple gene therapy products compete — as is beginning to emerge for hemophilia, where multiple gene therapy developers are pursuing approval — manufacturer competition creates meaningful pressure for price reduction, and some hemophilia gene therapies have been approved at prices below initial market expectations, partly in response to competitive dynamics. However, for the majority of gene therapy targets — rare diseases affecting small patient populations where the market can support only one or two products — competition will remain limited and price pressure minimal. The overall level of gene therapy pricing is more likely to be shaped by policy developments — particularly the expansion of government negotiating authority and international coordination on pricing — than by market competition alone. Patient advocacy organizations, health policy researchers, and public health institutions are increasingly coalescing around the access issue in ways that may create political conditions for meaningful policy reform within the decade.
Henry Jude writes about biotechnology and housing technology, focusing on the latest trends. He has 15 years of experience reporting on and analyzing advances in these fields. Holding both a BSc and an MSc in Biotechnology, he uses his scientific training to explain complex ideas clearly and show how new technologies can be applied in real life.
Leave a Reply